Thomas McNerney & Partners

Medical Device

is developing a continuous blood glucose sensor for patients with diabetes.

is developing a disposable drug delivery system which will initially be used for the treatment of Type 1 diabetes.

(formerly M2 Group Holdings, Inc.)

focused on developing minimally invasive technologies designed for the prevention of atrial fibrillation related stroke.

(acquired by Boston Scientific Corporation ticker: BSX)

is developing a next generation, implantable, artificial disc employing state of the art polymer technology.

is a global leader in medical and consumer eye health.

is a market leader in non-invasive cerebral oximetry and vital signs patient monitoring.

(NASDAQ ticker: CASM)

is a market leader in cryotherapy systems to treat cancerous and benign conditions.

is developing an improved glucose monitoring system for patients with diabetes.

developed and marketed bioabsorbable, polymer scaffolds for the treatment of articular cartilage and bone defects.

(acquired by Smith & Nephew plc ticker: SNN)

developed an innovative medical technology designed to facilitate the performance of endoscopic procedures.

(acquired by FUJIFILM Corporation)

is developing an implantable device to strengthen the esophageal sphincter for the treatment of gastro-esophageal reflux disease (GERD).

is developing a less invasive, next generation interspinous spacer for the treatment of lumbar spinal stenosis.